<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30251900</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1475-6374</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>33</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Dec</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of enzyme inhibition and medicinal chemistry</Title>                <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>            </Journal>            <ArticleTitle>Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents.</ArticleTitle>            <Pagination>                <MedlinePgn>1352-1361</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2018.1504041</ELocationID>            <Abstract>                <AbstractText>In our endeavour towards the development of effective anticancer therapeutics, a novel series of isoxazole-piperazine hybrids were synthesized and evaluated for their cytotoxic activities against human liver (Huh7 and Mahlavu) and breast (MCF-7) cancer cell lines. Within series, compounds 5l-o showed the most potent cytotoxicity on all cell lines with IC<sub>50</sub> values in the range of 0.3-3.7 μM. To explore the mechanistic aspects fundamental to the observed activity, further biological studies with 5m and 5o in liver cancer cells were carried out. We have demonstrated that 5m and 5o induce oxidative stress in PTEN adequate Huh7 and PTEN deficient Mahlavu human liver cancer cells leading to apoptosis and cell cycle arrest at different phases. Further analysis of the proteins involved in apoptosis and cell cycle revealed that 5m and 5o caused an inhibition of cell survival pathway through Akt hyperphosphorylation and apoptosis and cell cycle arrest through p53 protein activation.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Çalışkan</LastName>                    <ForeName>Burcu</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Pharmaceutical Chemistry, Faculty of Pharmacy , Gazi University , Ankara , Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sinoplu</LastName>                    <ForeName>Esra</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>b Department of Bioinformatics , Middle East Technical University , Ankara , Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>İbiş</LastName>                    <ForeName>Kübra</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Pharmaceutical Chemistry, Faculty of Pharmacy , Gazi University , Ankara , Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Akhan Güzelcan</LastName>                    <ForeName>Ece</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>b Department of Bioinformatics , Middle East Technical University , Ankara , Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Çetin Atalay</LastName>                    <ForeName>Rengül</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>b Department of Bioinformatics , Middle East Technical University , Ankara , Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Banoglu</LastName>                    <ForeName>Erden</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Pharmaceutical Chemistry, Faculty of Pharmacy , Gazi University , Ankara , Turkey.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>            <NlmUniqueID>101150203</NlmUniqueID>            <ISSNLinking>1475-6366</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>1RTM4PAL0V</RegistryNumber>                <NameOfSubstance UI="C034930">piperazine</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2015 Mar 1;136(5):E359-86</RefSource>                <PMID Version="1">25220842</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2008 Jan 15;122(2):444-51</RefSource>                <PMID Version="1">17918159</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12</RefSource>                <PMID Version="1">2359136</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Chem. 2012 Jan 26;55(2):587-96</RefSource>                <PMID Version="1">22136469</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 1996 Feb 15;16(4):1324-36</RefSource>                <PMID Version="1">8778284</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Biophys Res Commun. 2018 Feb 5;496(2):726-730</RefSource>                <PMID Version="1">29357281</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Molecules. 2014 Aug 12;19(8):12048-64</RefSource>                <PMID Version="1">25120056</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Oncol. 2012 Apr;6(2):155-76</RefSource>                <PMID Version="1">22440008</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Carcinogenesis. 2011 Aug;32(8):1107-21</RefSource>                <PMID Version="1">21464040</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Hepatol. 2012 Jun;56(6):1384-91</RefSource>                <PMID Version="1">22326465</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>FEBS J. 2010 Jan;277(1):2-21</RefSource>                <PMID Version="1">19843174</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Med Chem. 2017 Sep 8;137:292-309</RefSource>                <PMID Version="1">28605676</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Chem. 2012 Jan 26;55(2):576-86</RefSource>                <PMID Version="1">22136404</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bioorg Med Chem. 2006 Jun 15;14(12):4067-77</RefSource>                <PMID Version="1">16510288</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Ther Pat. 2016 Jul;26(7):777-97</RefSource>                <PMID Version="1">27177234</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2008 Apr 15;68(8):2850-60</RefSource>                <PMID Version="1">18413753</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Med Chem. 2014 Nov 24;87:140-9</RefSource>                <PMID Version="1">25247770</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Hepatol. 2012 Mar;56(3):704-13</RefSource>                <PMID Version="1">22120206</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2004 Feb 26;23(8):1489-97</RefSource>                <PMID Version="1">14647424</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Pharm Res. 2004 Apr;27(4):436-41</RefSource>                <PMID Version="1">15180310</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2011 Mar 4;144(5):646-74</RefSource>                <PMID Version="1">21376230</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bioorg Med Chem. 2012 Jun 15;20(12):3728-41</RefSource>                <PMID Version="1">22607880</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Med Chem. 2011 Feb;46(2):691-703</RefSource>                <PMID Version="1">21194809</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Physiol. 2013 Feb;228(2):292-7</RefSource>                <PMID Version="1">22777740</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Res. 2013 Aug;33(8):3027-32</RefSource>                <PMID Version="1">23898056</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Assay Drug Dev Technol. 2004 Aug;2(4):363-72</RefSource>                <PMID Version="1">15357917</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Med Chem. 2016 May 4;113:1-10</RefSource>                <PMID Version="1">26922224</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Prev Res (Phila). 2011 Jan;4(1):87-96</RefSource>                <PMID Version="1">21205739</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>EMBO Rep. 2013 Aug;14(8):686-95</RefSource>                <PMID Version="1">23846313</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Phytomedicine. 2016 Jan 15;23(1):42-51</RefSource>                <PMID Version="1">26902406</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Chem. 2017 Nov 22;60(22):9275-9289</RefSource>                <PMID Version="1">29053266</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Chem. 2013 Apr 25;56(8):3217-27</RefSource>                <PMID Version="1">23517011</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Invest New Drugs. 2011 Dec;29(6):1303-13</RefSource>                <PMID Version="1">20628892</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer. 2017 Apr 13;16(1):79</RefSource>                <PMID Version="1">28407774</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Chem. 2012 Apr 12;55(7):3058-65</RefSource>                <PMID Version="1">22409771</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Nov 6;8(63):107096-107108</RefSource>                <PMID Version="1">29291014</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bioorg Med Chem. 2014 Jun 15;22(12):3096-104</RefSource>                <PMID Version="1">24816066</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Molecules. 2017 Oct 29;22(11):null</RefSource>                <PMID Version="1">29109383</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thorac Oncol. 2018 Apr;13(4):576-584</RefSource>                <PMID Version="1">29247830</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):822-6</RefSource>                <PMID Version="1">8290606</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bioorg Med Chem Lett. 2015 Jan 15;25(2):285-7</RefSource>                <PMID Version="1">25488843</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2008 Dec 9;14(6):458-70</RefSource>                <PMID Version="1">19061837</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Chem. 2011 Oct 13;54(19):6761-70</RefSource>                <PMID Version="1">21851057</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bioorg Med Chem Lett. 2013 Aug 1;23(15):4419-23</RefSource>                <PMID Version="1">23787101</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2003 Oct 15;63(20):6707-15</RefSource>                <PMID Version="1">14583465</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Isoxazole</Keyword>            <Keyword MajorTopicYN="N">cytotoxicity</Keyword>            <Keyword MajorTopicYN="N">liver cancer</Keyword>            <Keyword MajorTopicYN="N">oxidative stress</Keyword>            <Keyword MajorTopicYN="N">piperazine</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30251900</ArticleId>            <ArticleId IdType="doi">10.1080/14756366.2018.1504041</ArticleId>            <ArticleId IdType="pmc">PMC6161610</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>